NetworkNewsBreaks – BriaCell Therapeutics Corp.
Post# of 69
BriaCell Therapeutics Corp. (OTCQB: BCTXF) (TSX.V: BCT), a biotechnology company developing targeted, safe treatments for cancer, this morning announced the appointment of Dr. Rebecca Taub, M.D., and Vaughn C. Embro-Pantalony to its board of directors. Dr. Saeid Babaei, Rahoul Sharan and Martin Schmieg have resigned from BriaCell’s board of directors, effective immediately. Since 2016, Taub has served as chief medical officer; executive vice president, R&D; and director of the board for Madrigal Pharmaceuticals (NASDAQ: MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics. She acted as privately-held Madrigal Pharmaceuticals Inc.’s chief executive officer and director of the board since its inception, through to its merger with Synta Pharmaceuticals Corp. Embro-Pantalony is chairman of the board of Soricimed Biopharma Inc., a private clinical-stage biopharma company developing targeted cancer therapies. He also serves as a director for Microbix Biosystems Inc. (OTC: MBXBF), a leading manufacturer of viral and bacterial antigens and reagents for the global diagnostics industry, where he was president and chief executive officer from 2012 to 2017.
“Both Dr. Taub and Mr. Embro-Pantalony are widely-regarded forces in the biopharma industry, bringing expert prowess in clinical oncology, corporate partnership strategy and board governance,” BriaCell’s Director and Acting Chairman of the Board Jamieson Bondarenko said in the news release. “On behalf of BriaCell’s Board of Directors, management team, and shareholders, I would like to thank Dr. Babaei, Mr. Sharan and Mr. Schmieg for their significant contributions to BriaCell and wish them the very best in their future ventures.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer